Why the study?
Does a monoclonal antibody against von Willebrand factor reduce thrombus formation and neointimal growth in a rabbit model of stenotic iliac artery injury?
Does a monoclonal antibody against von Willebrand factor reduce thrombus formation and neointimal growth in a rabbit model of stenotic iliac artery injury?
Answers are grounded in this paper and cite their sources.
Inhibition of von Willebrand factor significantly reduces fibrin-rich thrombus formation and neointimal growth in a rabbit model of stenotic arterial injury, suggesting a potential therapeutic target for post-intervention thrombosis.
OBJECTIVE: It has become clear that von Willebrand factor (vWF) plays important roles in platelet adhesion and aggregation under high blood-flow velocity conditions observed in stenotic atherosclerotic arteries. However, its roles in thrombus formation in vivo on diseased arteries have not been fully understood. We examined the contribution of vWF to thrombus formation and subsequent intimal growth by using a repeated balloon-injury model in rabbits. METHODS AND RESULTS: Rabbit iliac arteries 4 weeks after a first balloon injury showed 37% luminal stenosis by neointimal growth, and blood velocity increased by 2.1 times compared with that of uninjured arteries. The second balloon injury induced fibrin-rich thrombus formation on the injured neointima. Intravenous administration of a monoclonal antibody against vWF (AJW200, 1.0 mg/kg body weight) remarkably prevented botrocetin-induced platelet aggregation ex vivo for 2 days; moreover, thrombus formation, cell proliferation, and subsequent neointimal growth were significantly reduced at 30 minutes, 5 days, and 4 weeks, respectively, after the second balloon injury. CONCLUSIONS: These results indicate that vWF plays a potent role in fibrin-rich thrombus formation on the neointima under high blood-flow velocity conditions. Inhibition of plasma vWF activity might be effective for the reduction of thrombus formation and/or subsequent neointimal development after coronary interventions.
No takes yet. Share an insight, caveat, or question.
Yamashita et al. (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: